MELBOURNE, AUSTRALIA: Dimerix Limited (Dimerix), a biotechnology company developing novel treatments for kidney diseases, has announced the appointment of Dr David Fuller as its new Chief Medical Officer (CMO). Dr Fuller is a physician and a pharmaceutical executive with over 30 years of experience in drug development and regulatory affairs. He was previously the CMO of Race Oncology, a company focused on rare cancers.

Dr Fuller will lead the strategic delivery of Dimerix’s flagship ACTION3 Phase 3 clinical program for focal segmental glomerulosclerosis (FSGS), a rare and progressive kidney disease that affects about 210,000 people worldwide. The ACTION3 trial is currently recruiting patients globally and aims to demonstrate the efficacy and safety of Dimerix’s lead drug candidate, DMX-200, in FSGS.

Dr Fuller has a strong background in the Dimerix technology, having worked with the company before its public listing. He has also led several successful drug approvals in major markets, such as Moraxen (UK), Busulfex (US and EU), Xyrem (US) and Renagel (EU). He has designed and executed multiple clinical studies for both orphan and non-orphan drug products.